Clinical risk factors for diabetic retinopathy (DR), such as duration of disease and degree of glucose control, do not adequately predict disease progression in individual patients, suggesting the presence of a genetic component. Multiple smaller studies have investigated genotype-phenotype correlations in genes encoding vascular endothelial growth factor, aldose reductase, the receptor for advanced glycation end products, and many others. In general, reported results have been conflicting, due to factors including small sample sizes, variations in study design, differences in clinical end points, and underlying genetic differences between study groups. At this time, there is no confirmed association with any risk allele reported. As we continue to collect data from additional studies, the role of genetics in DR may become more apparent.
Introduction
Diabetic retinopathy (DR) is the leading cause of blindness in the US affecting people between the ages of 20 and 74 years 1 and is a prominent cause of visual impairment in the developing world. 2 Increased duration of diabetes, ineffective blood glucose control, and ineffective blood pressure control are the major risk factors for DR. 3 However, the incidence and progression of DR among patients with similar metabolic factors may vary substantially. 4 Furthermore, race, ethnicity, and sex appear to correlate with rates of DR. In the US, DR has been reported to be "slightly more prevalent" in men than in women (P=0.04), 5 but this finding has not been replicated on a worldwide scale. 6 All races and ethnicities are affected by DR, but some populations might be at higher risk. In the US, African-Americans and Hispanics have significantly higher reported rates of DR than non-Hispanic whites; 7 for example, in one series, non-Hispanic blacks had significantly higher rates than non-Hispanic whites of DR (P=0.01) and vision-threatening DR (P=0.01). 5 Reports on multiple populations from multiple nations suggest that African/Afro-Caribbean, South Asian, Latin American, and indigenous tribal populations have relatively higher rates of DR; the differences achieved statistical significance in some but not all of these studies. 7, 8 Taken together, these findings suggest a genetic influence on the development and progression of DR. Heritability has been estimated as high as 27% for DR and 52% for proliferative diabetic retinopathy (PDR). [9] [10] [11] This manuscript attempts to review the present literature regarding associations between various gene variants and DR. PubMed was searched using the terms "((("2012/01/01"[Date -Publication]: "3000"[Date -Publication])) AND (Diabetic AND Retinopathy)) AND Genetics" so that articles published following a previous review article on this subject 12 would be included. The intent was to create a relatively concise review to give the practicing clinician an appreciation for the current knowledge regarding genetic contributors to DR. This is not an all-inclusive document and it is likely that other genes and polymorphisms that have been studied with respect to DR have been missed by the search strategy.
Most genotype-phenotype studies of DR have used either individual candidate gene analyses or systematic genomewide association studies. 13 Many gene variants have been studied for possible associations with DR. These include well-studied genes ( Table 1) that are believed to contribute to the pathogenesis of diabetes or DR, as well as many more recently described and less understood gene variants (Table 2) , as well as genes for which no positive associations have been reported (Table 3 ).
Well-studied candidate genes
Four well-studied candidate genes, which encode proteins that are believed to be important in the pathogenesis of diabetes or DR, include vascular endothelial growth factor (VEGF), receptor for advanced glycation end products (RAGE), endothelial nitric oxide synthase (eNOS), and aldose reductase (AR). 
AR
AR converts glucose to sorbitol in the polyol pathway; 14 sorbitol cannot cross cell membranes but can accumulate in insulin-independent tissues, where it draws in water and produces osmotic stress. 15 Multiple studies have reported conflicting results regarding a potential association between AKR1B1 and DR. [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] For example, the C(−106)T polymorphism was significantly associated with DR in a series of 206 Iranian patients with type 2 diabetes (P=0.03) 27 but not in a series of 268 Chinese patients with type 2 diabetes. 28 A meta-analysis of 7,831 patients from 17 studies from Asia, South America, Europe, and Australia reported a significant association between the C(−106)T polymorphism and DR in patients with type 1 diabetes (odds ratio [OR] =1.78, 95% confidence interval [CI] =1.39-2.28) but not type 2. 29 eNOS eNOS is involved in regulating vascular tone by inhibiting smooth muscle contraction and platelet aggregation. 30 Two studies (both including patients with type 1 and type 2 diabetes), a meta-analysis including nine studies comprising 3,145 patients from multiple nations, 31 and one including 1,446 Asian Indian patients, 32 reported that the 4a allele of a variable number tandem repeat (VNTR) in the gene was negatively associated with DR (P=0.005) 31 and PDR (P=0.03). 32 Another meta-analysis of 16 studies comprising 6,664 patients reported that the AA genotype of 27VNTR (4a/b) was negatively associated with DR in type 2 diabetes (OR =0.75, 95% CI =0.65-0.88), but only in African populations (of note, the analysis included two studies containing a total of 1,447 patients of African ancestry from the US and Tunisia) and not in Caucasian or Asian populations. 33
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Positive assn w/ PDR in T2DM (P=0.0048) No sig assn w/ PDR in T2DM Bengali Hindu (493 pts) Clinically assessed 80
No sig assn w/ DR in T2DM Abbreviations: T2DM, type 2 diabetes mellitus; DR, diabetic retinopathy; Nw, north west; CFH, complement factor H; CFB, complement factor B; PDR, proliferative diabetic retinopathy; CHN2, chimerin 2; NPDR, nonproliferative diabetic retinopathy; OR, odds ratio; CI, confidence interval; EPO, erythropoietin; GSTT1, glutathione S-transferase theta 1; GSTM1, glutathione S-transferase mu 1; iCAM-1, intercellular adhesion molecule-1; T1DM, type 1 diabetes mellitus; iFN-γ, interferon gamma; iL-6, interleukin-6; iL-10, interleukin-10; MCP-1, monocyte chemoattractant protein-1; PAi-1, plasminogen activator inhibitor-1; PPARγ, peroxisome proliferator-activated receptor gamma; TCF7L2, transcription factor 7-like-2; TGF-β1, transforming growth factor beta 1; TLR4, toll-like receptor 4; TNF-α, tumor necrosis factor alpha; MnSOD, manganese superoxide dismutase; UCP1, uncoupling protein 1; UCP2, uncoupling protein 2; assn, association; sig, significant; pts, participants; w/, with. 
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Genetics and diabetic retinopathy A series of 577 Slovenian patients reported that the A allele of 27VNTR (4a/b) was significantly associated with PDR in type 2 diabetes (P=0.01). 34 Other studies, however, reported no significant associations between eNOS polymorphisms and DR in type 2 diabetes. [35] [36] [37] RAGe RAGE regulates oxidative stress and endothelial function in type 2 diabetes. 38 A series of 577 Malaysian patients reported no associations between the −429 T/C polymorphism or the −374T/A polymorphism and DR in type 2 diabetes. 39 A meta-analysis of eleven studies containing a subgroup of seven studies including 3,339 Asian, African, and Caucasian patients reported that the AA genotype of the −374T/A polymorphism was negatively associated with DR in type 2 diabetes (OR =0.64, 95% CI =0.42-0.99). 40 Alternatively, a series of 758 North Indian patients reported a significant association between the homozygous Ser82 genotype of the Gly82Ser polymorphism with DR in type 2 diabetes (P,0.033). 41 However, one series of 283 Malaysian patients with type 2 diabetes 42 and one meta-analysis of over 1,000 patients from 29 studies from the US, Europe, and Asia 43 reported no associations between RAGE polymorphisms and DR.
veGF
The best studied gene in the context of DR is VEGF. VEGF is involved in the pathogenesis of PDR and diabetic macular edema, and anti-VEGF drugs have become widely used in the treatment of DR. Four well-studied polymorphisms include rs833061 (−460T/C), rs699947 (−2578C/A), rs2010963 [(405G/C) and (634 G/C)], and rs3025039 (+936C/T).
rs833061 (−460T/C)
A study of 493 Bengali Hindu patients reported a significant association between the C allele and PDR in type 2 diabetes (P=0.0043), and a significant negative association between the TT genotype and PDR (P=0.0126). 44 An 11-study metaanalysis comprising six studies (1,654 patients of Asian and Caucasian backgrounds) also reported that the C allele was significantly associated with PDR (P=0.02) and DR (P=0.02) in type 2 diabetes. 45 Another 11-study meta-analysis including three relevant studies of the rs833061 polymorphism (746 patients of Asian background) also reported that rs833061 was significantly associated with DR in type 2 diabetes (P=0.02). 46 However, a study of 376 Han Chinese patients reported that the C allele was negatively associated with non-PDR (P=0.013), but there was no association with PDR. 47 A separate series of 500 Chinese patients reported no association with DR in type 2 diabetes. 48
rs699947 (−2578C/A)
A meta-analysis including eight studies (2,402 patients of Asian and European backgrounds) reported that rs699947 was significantly associated with DR in type 2 diabetes. 49 A study of 500 Chinese patients also reported that this polymorphism was significantly associated with DR in type 2 diabetes (OR =3.54, 95% CI =1. 12-11.19 ). 48 A meta-analysis of 1,702 patients (1,124 of which were Asian) from six studies reported that rs699947 was significantly associated with DR in type 2 diabetes in Asian (P=0.0002) but not Caucasian patients. 50 A study of 148 Egyptian patients reported a significant association between this polymorphism and DR in patients having diabetes (type unspecified) for 20 years or more (P,0.001). 51 However, a 6-study meta-analysis of 2,208 patients (both type 1 and type 2) from Caucasian and Asian backgrounds, 45 an 11-study meta-analysis including six relevant studies of 1,868 patients with type 2 diabetes from Caucasian and Asian backgrounds, 46 and a series of 1,040 Chinese patients with type 2 diabetes 52 reported no associations.
rs2010963 [(405G/C) and (634 G/C)]
A study of 372 Bengali Hindu patients reported that the 405 C allele was significantly associated with PDR (P=0.0007) but not nonproliferative diabetic retinopathy (NPDR) in type 2 diabetes. 53 A meta-analysis comprising nine studies of 2,947 patients (mixed populations) 54 also reported a significant association of rs2010963 with DR in type 2 diabetes (P=0.03), but this result was refuted by a 7-study meta-analysis of 2,104 patients with type 2 diabetes of Asian and Caucasian backgrounds. 46
rs3025039 (+936C/T)
A meta-analysis including four studies and 1,147 Asian patients reported a significant association between rs3025039 and DR in type 2 diabetes (P=0.01). 46 A study of 372 Bengali Hindu patients reported that the T allele was significantly associated with PDR (P=0.0002) but not NDPR in type 2 diabetes. 53 A study of 1,040 Chinese patients also reported no association between +936C/T and DR in type 2 diabetes. 52 Other VEGF polymorphisms 
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Hampton et al and DR in type 2 diabetes. 55 A study of 500 Chinese patients reported a significant association between rs13207351 and DR in type 2 diabetes (OR =3.76, 95% CI =1. 21-11.71 ). 48 In a series of 372 Bengali Hindu patients, no associations were reported between the rs1570360 (−1154 G/A) or rs2071559 (−604 A/G) polymorphisms and NPDR or PDR in type 2 diabetes. 53
Newer candidate genes Adiponectin
Adiponectin, encoded by ADIPOQ, is involved in regulating glucose levels as well as fatty acid breakdown. 56 The rs2241766 (T45G) polymorphism T allele of ADIPOQ was significantly associated with DR in type 2 diabetes in a study of 672 Punjab Indian patients (P=0.0007), 57 but not in a study of 517 Chinese patients. 58 
Complement factors H and B
Complement factors H (CFH) and B (CFB), both integral mediators of the alternative pathway of the immune system, have also been investigated. 59, 60 The CFH rs800292 (I62V) A allele was negatively associated with DR in a series of 552 Chinese patients with type 2 diabetes (P=0.04). 61 In the same series, the CFB rs1048709 (R150R) A allele was significantly associated with DR in type 2 diabetes (P=0.035). 61 In addition, the CFH rs1410996 polymorphism was not significantly associated with PDR in type 1 diabetes in a series of 147 Spanish patients. 62
Chimerin 2
Chimerin 2 activity is involved in cell migration and proliferation. 63 65 erythropoietin Erythropoietin has been reported to stimulate angiogenesis, vasoconstriction-dependent hypertension, and smooth muscle fiber proliferation. 66 A series of 792 Chinese patients reported that the rs507392 and rs551238 CC genotypes were negatively associated with DR (P=0.027 and P=0.016, respectively) and PDR (P=0.002 and P=0.002, respectively) in type 2 diabetes. 67 However, other series reported no associations between erythropoietin polymorphisms and DR. 48, 65 Glutathione S-transferase theta 1 and glutathione S-transferase mu 1
Glutathione S-transferase theta 1 (GSTT1) and glutathione S-transferase mu 1 (GSTM1) neutralize toxins and products of oxidative stress. 68 A study of 604 Slovenian patients reported a significant association between the GSTT1 null genotype and DR in type 2 diabetes (P,0.001) and also reported that the GSTM1 null genotype was negatively associated with DR in type 2 diabetes (P,0.001). 69 A series of 115 Iranian patients reported a significant association between the GSTM1 null genotype and DR in type 2 diabetes (P=0.04). 70 A meta-analysis of 3,463 subjects from multiple studies reported that both null genotypes were significantly associated with DR in type 1 and type 2 diabetes (P,0.0001 for GSTT1 null genotype, P=0.0005 for GSTM1 null genotype). 71 However, a series of 605 Southern Iranian patients reported no associations between null genotypes in GSTT1 or GSTM1 and DR in type 2 diabetes. 72 intercellular adhesion molecule-1
Intercellular adhesion molecule-1 (ICAM-1) binds integrins and is normally expressed by immune cells and endothelial cells; it participates in Class I major histocompatibility complex-mediated antigen processing/presentation. 73 The AA genotype of ICAM-1 rs5498 (K469E) polymorphism was significantly associated with DR in a cohort of 356 South Indian patients with type 2 diabetes (P=0.012). 74 In addition, a meta-analysis of three studies comprising 1,232 Asian patients reported a significant negative association between the ICAM-1 rs5498 (K469E) GG genotype and PDR in type 2 diabetes (P=0.016). 75 However, a series of 500 Chinese patients with type 2 diabetes, 48 a meta-analysis of seven studies including 3,411 Asian and Caucasian patients with type 2 diabetes, 76 and a meta-analysis of seven studies including 2,003 Asian and Caucasian patients with type 2 diabetes 77 have reported no associations between ICAM-1 polymorphisms and DR.
interferon gamma
Interferon gamma (IFN-γ) is a soluble cytokine with antiviral, immunoregulatory, and antitumor/antiproliferative properties and is a potent activator of macrophages. 78 A study of
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Genetics and diabetic retinopathy 493 Bengali Hindu Indians reported a significant association between the IFN-γ rs 2430561 (+874 T/A) T allele and PDR in type 2 diabetes (P=0.0011). 44 However, a study of 102 Brazilian patients reported no association between the same polymorphism and DR in type 2 diabetes. 79 interleukin-6 and interleukin-10
Polymorphisms in interleukin-6 (IL-6) and interleukin-10 (IL-10) were also investigated. The rs1800896 (−1082) G allele in IL-10 was significantly associated with PDR in a study of 493 Bengali Hindu patients with type 2 diabetes (P=0.0048). 80 However, another study of 102 Brazilian patients reported that this polymorphism, plus two others in IL-10 [rs1800871 (−819 C/T) and rs1800872 (−592 C/A)] and one in IL-6 [rs1800795 (−174 C/G)], did not associate with DR in type 2 diabetes. 79
Monocyte chemoattractant protein-1
Monocyte chemoattractant protein-1 (MCP-1) is a chemokine specific for monocytes and basophils. 81 A series of 590 Korean patients reported a significant association between MCP-1 rs1024611 (−2518 A/G) AA genotype and PDR in type 2 diabetes (P=0.009). 82 Alternatively, a study of 1,043 Han Chinese patients reported that the G allele of the same polymorphism was significantly associated with high-risk PDR in type 2 diabetes (P=0.02), although no association was reported with NDPR. 83 Two subsequent studies of 758 Japanese patients with type 2 diabetes (P=0.030) 84 and 517 Han Chinese patients with type 2 diabetes (P=0.026) 85 also reported that the G allele, not the A allele, was significantly associated with DR.
Manganese superoxide dismutase
Manganese superoxide dismutase binds superoxide byproducts from oxidative phosphorylation. 86 A study of 280 Northern Iranian patients reported that the A16V (C47T) polymorphism AV genotype was significantly associated with DR (P,0.0001), 87 although a series of 758 Northern Indian patients reported no association between this polymorphism and DR in type 2 diabetes. 41
Plasminogen activator inhibitor-1
Plasminogen activator inhibitor-1 is the main inhibitor of tissue plasminogen activator and plays a major role in the regulation of intravascular fibrinolysis. 88 Impaired fibrinolysis is involved in the pathogenesis of DR in patients with type 2 diabetes. 89 A subgroup analysis of a meta-analysis comprising five studies of 1,936 Caucasian patients reported that the 675 4G/5G polymorphism was significantly associated with DR in type 2 diabetes (P=0.003); this association was not observed in the overall 9-study analysis of 2,676 patients of Caucasian, Asian, and Pima Indian backgrounds. 90 A separate meta-analysis comprising ten studies of 5,768 type 1 and type 2 diabetic patients of Asian and European descents, respectively, reported no significant associations with DR. 91
Peroxisome proliferator-activated receptor gamma
Peroxisome proliferator-activated receptor gamma is a regulator of adipocyte differentiation 92 and has been implicated in the pathology of obesity, diabetes, and other disorders. 93 A meta-analysis comprising eight studies of 5,170 Caucasian and Asian patients reported that the rs1801282 (Pro12Ala) polymorphism Ala allele was negatively associated with DR in type 2 diabetes in Caucasians only (P=0.01). 94 Similarly, a series of 573 Pakistani patients also reported a significant negative association between the Ala allele and PDR in type 2 diabetes (OR =0.4, 95% CI =0.2-0.8). 95 However, a series of 1,907 patients from the US with type 1 diabetes, 65 a series of 2,963 Finnish patients with type 1 diabetes, 96 and a series of 792 Chinese patients with type 2 diabetes 97 reported no associations.
Transcription factor 7-like 2
Variants of transcription factor 7-like 2, a protein involved in blood glucose homeostasis, are associated with increased risk for type 2 diabetes. 98 A series of 325 Italian patients reported significant associations between the rs7903146 (P=0.037) and rs12255372 (P=0.014) polymorphisms and DR in type 2 diabetes. 99 A study of 1,139 Caucasian patients with type 2 diabetes and 789 Caucasian patients with type 1 diabetes reported a significant association between the rs7903146 T allele and PDR in type 2 patients only (P=0.001). 100 However, a series of 1,129 Chinese patients with type 2 diabetes, 101 a series of 2,963 Finnish patients with type 1 diabetes, 96 a series of 792 Chinese patients with type 2 diabetes, 97 and a meta-analysis of over 1,000 patients from multiple backgrounds with type 2 diabetes 102 reported no associations.
Transforming growth factor beta 1
Transforming growth factor beta 1 is involved in many cellular functions such as proliferation and differentiation. 103, 104 A study of 102 Brazilians reported that the rs1800471 (R25P) G allele was significantly associated with DR in type 2 diabetes (P=0.018). 79 A meta-analysis of 1,101
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Hampton et al patients including patients from multiple ethnic groups reported that the rs1982073 (T869C) L allele was negatively associated with DR in type 2 diabetes (P=0.03). 105 However, a study of 361 British Caucasian patients reported no significant associations between the rs1982073 (T869C) or rs1800471 (R25P) polymorphisms and DR in type 1 diabetes. 106 Toll-like receptor 4
Toll-like receptor 4 helps mediate the innate immune response and has been associated with age-related macular degeneration 107, 108 and Behçet's disease. In two series, one of 698 North Indian patients and one of 510 Han Chinese patients, the rs1927914 (TLR4_2437) polymorphism was significantly associated with DR in type 2 diabetes (P=0.05, P=0.018, respectively). 109, 110 The study of 698 North Indian patients also reported a significant association between the rs10759931 (TLR4_2437) AG genotype and DR in type 2 diabetes. 109 Tumor necrosis factor alpha Tumor necrosis factor alpha (TNF-α) is involved in the regulation of processes like cell proliferation, differentiation, apoptosis, lipid metabolism, and blood vessel permeability. 111 A series of 745 Brazilian-Caucasian patients reported that the rs1800629 (TNF-308 G/A) A allele was significantly associated with PDR in type 2 diabetes (P=0.035). 112 Similarly, a study of 493 Bengali Hindu patients reported that the rs361525 (TNF-238) A allele was significantly associated with PDR in type 2 diabetes (P=0.0001). 80 However, a study of 672 Punjab Indian patients with type 2 diabetes, 57 a series of 102 Brazilian patients with type 2 diabetes, 79 and a meta-analysis of 3,041 patients from Europe and Asia with type 2 diabetes 113 reported no associations between the rs1800629 (TNF-308 G/A) polymorphism and DR.
Uncoupling proteins 1 and 2
Uncoupling proteins 1 and 2 (UCP1 and UCP2) are involved in regulation of cellular metabolism. 114 A study of 257 Brazilian patients reported that the rs1800592 (−3826A/G) GG genotype of UCP1 was significantly associated with DR in type 1 diabetes (P=0.043). 115 A series of 792 Chinese patients reported that the rs1800592 (−3826A/G) GG genotype of UCP1 was significantly associated with PDR (P=0.03) but not NPDR in type 2 diabetes. 97 A separate series of 958 Chinese patients reported that the rs659366 G allele of UCP2 was significantly associated with PDR (P=0.016) but not NPDR in type 2 diabetes. 116
Candidate genes with no reported associations Hematopoietically expressed homeobox
Hematopoietically expressed homeobox is involved in embryogenesis, cellular transcriptional misregulation, and pancreatic β-cell development. 117 Two studies investigated the rs7923837 polymorphism in 1,129 type 2 diabetic Chinese patients 101 and rs1111875 polymorphisms in 2,963 type 1 diabetic Finnish patients, 96 respectively, and reported no associations with DR.
Solute carrier family
Solute carrier family (SLC) proteins are expressed mainly in the pancreatic islets of Langerhans and play a role in insulin secretion. 118 A series of 1,129 Chinese patients with type 2 diabetes, 101 a series of 2,963 Finnish patients with type 1 diabetes, 96 a series of 211 Malaysian patients with type 2 diabetes, 119 and a series of 6,682 patients from Singapore with type 2 diabetes 120 reported no associations between SLC and DR.
In addition to the genes discussed above, many other polymorphisms have been studied. Table 4 summarizes these relatively new candidate genes that may have bearing on DR.
Discussion
Many individual studies have reported statistically significant associations between various polymorphisms and features of DR. However, many of the results are conflicting and it is difficult to draw definitive conclusions based on the available literature. At this time, there is no confirmed association with any risk allele reported. This may be due to a variety of reasons.
There are multiple challenges in designing a genetic association study, especially with respect to DR. The genetic contribution to DR appears to be relatively modest, requiring larger sample sizes to achieve sufficient statistical power. Determining the number of patients required to achieve sufficient statistical power is complex and is best performed by statisticians or those with experience in this area. In at least some of the studies reviewed here, it is not certain how (or if) power calculations were performed.
Further, DR is a qualitative trait that cannot be easily reduced to a numerical value. The modified Airlie House Classification is a numerical system based on stereoscopic photographs of seven standard fields, resulting in a grade ranging from 10 (no retinopathy) to 85 (severe vitreous hemorrhage or retinal detachment involving the macula). 121 However, this complex classification system is rarely used Abbreviations: PON, paraoxonase; OR, odds ratio; CI, confidence interval; OPG, osteoprotegerin; KDR, kinase insert domain receptor; VEGFR, vascular endothelial growth factor receptor; SNP, single nucleotide polymorphism; vDR, vitamin D receptor; SLMAP, sarcolemma associated protein; FABP2, fatty acid binding protein-2; Romo-1, reactive oxygen species modulator 1; FABP2, fatty acid binding protein-2; eL, endothelial lipase; iGF-1, insulin-like growth factor 1; GwAS, genome-wide association study; CNR1, cannabinoid type 1 receptor gene; ALDH2, aldehyde dehydrogenase 2; MTHFR, methylenetetrahydrofolate reductase; SDH, sorbitol dehydrogenase; DR, diabetic retinopathy; assn, association; sig, significant; w/, with; pts, participants; T2DM, type 2 diabetes mellitus; T1DM, type 1 diabetes mellitus; LD, linkage disequilibrium; PDR, proliferative diabetic retinopathy.
today. Specific clinical end points such as any DR, NPDR, PDR, or diabetic macular edema may differ across studies. In addition, some patients have retinal changes that mimic early DR, which may further confound studies. 122, 123 Type 2 diabetes mellitus is associated with relatively late disease onset as well as reduced life span, so the parents of patients may not be available for study. 3 There is likely substantial heterogeneity within individual studies, including duration of diabetes, age at first diagnosis (if known), strictness of metabolic control, and comorbidities such as hypertension, hypercholesterolemia, and others. In addition, there is likely substantial heterogeneity across different studies, due to underlying differences in study populations. Different studies were conducted on different continents with patients of different races and ethnicities. Further, multiple meta-analyses combined these studies in different ways. Some studies used self-reported data, which may introduce bias because patients may be more likely to report severe retinopathy as opposed to milder disease. 124 At this time, genetic associations with DR are an intriguing area of research, but are not helpful in routine clinical management. As we collect more information about genotype-phenotype correlations, our understanding may increase. Ultimately, this information may help to stratify patients into different risk groups, which may positively impact clinical management decisions. In addition, this information may lead to the investigation of future drug targets.
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